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Ranolazine and Silent Ischemia
I read with interest the paper by Stone et al. (1), in which the authors
investigated the relationship between ST-segment depression and the
rate-pressure product during exercise. Based on their findings, they
suggested that ranolazine’s beneficial action is most likely primarily
due to improvement of regional coronary blood flow in areas of
myocardial ischemia. I do not refute that statement, but I would like
to remind the readers that the current hypothesis of the mechanism of
action of ranolazine is that it works only after myocardial ischemia has
been present. When that happens, the late sodium channel remains
open, leading to intracellular sodium overload, and the sodium–
calcium exchanger then leads to intracellular calcium overload, which
results in increased calcium ions intracellularly and impaired diastolic
relaxation and increased tension. Ranolazine inhibits the myocardial
late inward sodium current associated with ischemia and thus breaks
up the cycle (2).
The authors emphasize in their article that under low stress conditions
of exercise where there was mild ischemia, the ranolazine did not seem to
be effective; however, as the ischemia became more pronounced, the
anti-ischemic effects of ranolazine became more marked.
My question to the investigators is this: Since it has been shown
many times that patients with chronic stable angina have multiple aepisodes of asymptomatic cardiac ischemia, is it possible or
probable that these multiple episodes of silent cardiac ischemia are
prevented from becoming manifest symptoms of myocardial isch-
emia (i.e., angina) by the drug ranolazine?
I suspect that the only way one could find the answer is to have
chronic ambulatory electrocardiogram (ECG) monitoring of these
patients. I know that patients who were in the MERLIN–TIMI
36 (Metabolic Efficiency With Ranolazine for Less Ischemia in
Non–ST-Segment Elevation Acute Coronary Syndromes–
Thrombolysis In Myocardial Infarction 36) trial (3) had 7 days of
ambulatory ECG monitoring, but the published study revealed
that only arrhythmias were assessed. Would it be possible to go
back and investigate those ambulatory ECGs to see whether or not
silent ST-segment depression was present on several occasions
without any manifestations of angina?
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Reply
Dr. Conti raises an interesting conceptual point regarding our paper
(1) concerning the implications of treatment with ranolazine. If
anolazine were to render each ischemic episode less severe than an
schemic episode in the absence of ranolazine, then despite a reduction
n symptomatic ischemia (i.e., angina), ranolazine may be associated
ith more frequent asymptomatic ischemia and, by inference, may
xpose the patient to an increased risk of cardiac events.
The fundamental premise implicit in this question, however,
hat asymptomatic episodes of myocardial ischemia represent less
evere ischemia than symptomatic episodes, has not been demon-
trated in any clinical study. Episodes of asymptomatic ischemia
ecorded during ambulatory electrocardiogram (ECG) recordings
emonstrate the same ECG characteristics of ischemia severity as
pisodes of symptomatic ischemia (2). There is no evidence to
upport the notion that asymptomatic ischemia is asymptomatic
ecause it is less severe than symptomatic ischemia and, conse-
uently, does not reach an “angina threshold.”
As Dr. Conti noted, patients in the MERLIN–TIMI 36 (Metabolic
fficiency With Ranolazine for Less Ischemia in Non–ST-Segment
levation Acute Coronary Syndromes–Thrombolysis In Myocardial
nfarction 36) trial had 7 days of continuous ECG recordings following
dmission with a non–ST-segment elevation acute coronary syndrome.
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fact, assess ischemic episodes throughout the recording period and found
that there was not a significant difference in the rate of positive ECG
recordings for ischemia (19.9% on ranolazine vs. 21.0% on placebo; p
0.21) (3). The investigators did not specifically report the individual
number of symptomatic and silent episodes of myocardial ischemia or
their duration duringECGmonitoring on ranolazine versus placebo.The
aggregate risk of cardiovascular death or myocardial infarction in the
MERLIN–TIMI 36 trial was similar for patients taking ranolazine and
placebo and in the patient subset that was enrolled with prior chronic
angina, fewer recurrent ischemic episodes were observed in the
ranolazine-treated group after 1-year follow-up, and exercise durationwas
significantly greater (4). Thus, the hypothesis that converting symptom-
atic to silent ischemic episodes with ranolazine is harmful is unlikely to be
valid.
It would be interesting for the TIMI investigators to address the
specific question of the proportion of the number and duration of
asymptomatic and symptomatic ischemia episodes in patients taking
ranolazine versus placebo from their extensive continuous ECG
database and to correlate these findings with 1-year outcome. This
type of analysis would expand our knowledge on ranolazine treatment
effects and could potentially more completely address the question
that Dr. Conti has raised.
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Clopidogrel After Coronary
Artery Bypass Graft Surgery
Insufficient Evidence
We recently read the interesting study by Sørensen et al. (1), which
valuated the efficacy of clopidogrel after coronary artery bypass graft
urgery (CABG) following a recent myocardial infarction (MI). Usingdata from 3,545 patients, the authors reported a lower risk of death
and the combined endpoint of death or recurrent MI in patients who
received clopidogrel after surgery. Based on their results, the authors
recommend that a “focus on discharge clopidogrel treatment of these
patients should be made” (1).
Because their study was nonrandomized, the authors used multi-
variate and propensity-score analyses to control for possible confound-
ers. Interestingly though, no adjustment was made for the use of on-
or off-pump CABG. In theory, any benefit associated with clopi-
dogrel after CABGwould be seen in an improvement in graft patency
and the prevention of myocardial events. However, clopidogrel did
not significantly reduce the incidence of recurrent MI, cardiovascular
death, or the need for repeat revascularization in this study. How
could clopidogrel lower the risk of death and yet not reduce the
incidence of myocardial events after CABG? Although no explana-
tion was provided by the authors, perhaps this finding relates to
residual confounding. Clopidogrel may have been administered pref-
erentially to healthier patients in this cohort who were believed to have
a better chance for long-term survival.
Sørensen et al. (1) imply in their paper that clopidogrel is
underused after CABG, referring to the current guidelines that
recommend postoperative clopidogrel treatment for 9 to 12 months
for patients who undergo CABG following MI (2). This recommen-
dation was based primarily on data from the Clopidogrel in Unstable
Angina to Prevent Recurrent Ischemic Events (CURE) trial that
reported significantly fewer adverse cardiac events amongMI patients
treated with the combination of clopidogrel and aspirin compared
with aspirin alone, even if they ultimately underwent CABG (3).
However, subgroup analysis later revealed that the benefit of com-
bined antiplatelet therapy was entirely preoperative while patients
were awaiting surgery. No benefit was seen for clopidogrel use after
CABG in the CURE trial (4). Therefore, it is not surprising that
many surgeons do not routinely prescribe clopidogrel after CABG.
Because of the lack of prospective data in the field (5), we recently
performed the CASCADE (Clopidogrel After Surgery for Coronary
Artery DiseasE) study (NCT00228423), a randomized, placebo-
controlled trial to evaluate whether the addition of clopidogrel to aspirin
would inhibit the process of saphenous vein graft disease afterCABG (6).
Compared with aspirin alone, the combination of aspirin plus clopidogrel
did not significantly reduce vein graft intimal hyperplasia 1 year after
CABG, as assessed by intravascular ultrasound. Although CASCADE
was not powered for angiographic or clinical outcomes, we also did not
see a significant difference in vein graft patency or cardiovascular events
between the 2 treatment groups (7). Power calculations based on
CASCADE determined that a sample size of 8,000 grafts would be
required to demonstrate an improvement in patency with clopidogrel.
We doubt a future trial of this size will ever be performed.
In summary, based on the data available to date, we do not believe
that compelling evidence exists to support the routine use of clopi-
dogrel after CABG.
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